[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fQxniVS2oS3-iPkUv3k7TG9S7bEAVemE7bFA3FdFQ9zc":8,"$fTbDvvyI9wFzUCITb-2Acj9NeuU8tBXQ9H1TmUW8-Xo0":55,"$fdvagHPdMSJrvdkHOam54oCXGU10FAEOt9kIhP7JGjS4":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},61749,868960,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//qToouzd3wNZJDyz176JvWbOwPLYeq3AU.png","王淑倩","浙江大学医学院附属第一医院","甲状腺乳腺外科","副主任医师",29,0,"乳腺癌HER2阳性靶向治疗用药全指南：帕妥珠单抗与曲妥珠单抗安全手册","","https://ystcdn.venuertc.com/venue/AI/1b9953e4-98ce-4414-ad01-079d2669add8.jpg","\u003C!-- 乳腺癌HER2阳性患者靶向药物科普专题：帕妥珠单抗与曲妥珠单抗安全用药全攻略 -->\n\n\u003Cdiv class=\"her2-material-main\">\n\n  \u003Ch1 id=\"material_title\" class=\"her2-material-h1\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\n    乳腺癌HER2阳性靶向治疗用药全指南：帕妥珠单抗与曲妥珠单抗安全手册\n  \u003C/h1>\n  \u003Cdiv class=\"her2-material-lead\">\n    说起乳腺癌靶向治疗，帕妥珠单抗和曲妥珠单抗是最常使用的两种药物。它们属于单克隆抗体，主要针对HER2蛋白阳性的患者。正确、安全使用这类靶向药物，有许多不起眼但至关重要的细节。本文将从7个关键角度，帮助大家全面了解帕妥珠单抗与曲妥珠单抗的安全用药要领，确保疗效最大化，减少各种用药风险。\n  \u003C/div>\n\n  \u003C!-- 01 药品基础与作用机制 -->\n  \u003Csection class=\"her2-material-section\">\n    \u003Cdiv class=\"her2-material-subtitle-bg\">\n      \u003Ch2 class=\"her2-material-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 药品基础与作用机制 🧬\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"her2-material-content\">\n      \u003Cp>\n        帕妥珠单抗（Pertuzumab）和曲妥珠单抗（Trastuzumab）都属于重组人源化单克隆抗体，主要针对HER2蛋白。两者都可静脉给药，规格常见为注射用粉针剂（每瓶含420mg、150mg不等）。\u003Cbr>\n        \u003Cstrong>作用机制上：\u003C/strong>曲妥珠单抗结合HER2受体的第IV结构域，阻断受体信号传导，使异常增殖过程被抑制；而帕妥珠单抗则作用于第II结构域，通过阻止HER2受体的二聚化，进一步抑制细胞异常分裂。多数情况下，这两种抗体会联合使用，以形成“双靶”作用，提高抑制效率。\n      \u003C/p>\n      \u003Cul class=\"her2-material-ul\">\n        \u003Cli>曲妥珠单抗是HER2单靶药物，“老牌”用药。\u003C/li>\n        \u003Cli>帕妥珠单抗是HER2二聚化抑制剂，新一代“二靶”药物。\u003C/li>\n        \u003Cli>二者具有协同作用，可显著提升总生存期。\u003Cspan class=\"her2-material-emoji\">🔬\u003C/span>\u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        \u003Cspan class=\"her2-material-mark\">正确做法：\u003C/span>使用前必须明确患者HER2蛋白强阳性（一般需要免疫组化3+或FISH检测阳性）。单药使用时疗效较弱，临床常规为二者联合化疗。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 02 注射方法与给药时机 -->\n  \u003Csection class=\"her2-material-section\">\n    \u003Cdiv class=\"her2-material-subtitle-bg\">\n      \u003Ch2 class=\"her2-material-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 注射方法与用药时机 💉\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"her2-material-content\">\n      \u003Cp>\n        这两款药物都为静脉注射剂型，使用时主要注意以下几个细节：\n      \u003C/p>\n      \u003Cul class=\"her2-material-ul\">\n        \u003Cli>\n          \u003Cspan class=\"her2-material-mark\">用药顺序：\u003C/span>帕妥珠单抗与曲妥珠单抗可以联合使用，通常不要求严格先后，但多建议同一疗程中先帕妥后曲妥。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"her2-material-mark\">首次和维持剂量：\u003C/span>首次使用需按体重计算负荷剂量，后续每3周重复一次维持剂量。剂量设置需严格依医嘱，不可自行增减。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"her2-material-mark\">注射时间控制：\u003C/span>初次输注时间通常较长，需1.5小时以上。后续可根据耐受情况缩短，但最短也需30分钟。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"her2-material-notice\">用药仅限医院环境，由有经验的医护操作！\u003C/span>\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        \u003Cspan class=\"her2-material-mark\">特别提醒：\u003C/span>药物应严格避免推注及肌肉注射，只能经静脉点滴缓慢输入。\n      \u003C/p>\n      \u003C!-- 案例1 -->\n      \u003Cdiv class=\"her2-material-case\">\n        \u003Cstrong>案例：\u003C/strong>一位63岁女性，乳腺外科术后，依据体重按规定负荷剂量首次使用帕妥珠单抗和曲妥珠单抗，联合静点，疗程维持稳定，未见严重不良反应。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 03 剂型、溶解与储存细则 -->\n  \u003Csection class=\"her2-material-section\">\n    \u003Cdiv class=\"her2-material-subtitle-bg\">\n      \u003Ch2 class=\"her2-material-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 剂型、溶解与储存细则 📦\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"her2-material-content\">\n      \u003Cp>\n        帕妥珠单抗与曲妥珠单抗均为冻干粉注射剂，用生理盐水稀释，溶解时严格消毒操作，避免配伍污染。\n      \u003C/p>\n      \u003Cul class=\"her2-material-ul\">\n        \u003Cli>\n          \u003Cspan class=\"her2-material-mark\">溶制方式：\u003C/span>需用注射用水或0.9%氯化钠注射液稀释，注意轻柔旋转，禁止剧烈晃动！\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"her2-material-mark\">稀释浓度：\u003C/span>应参照说明书及医嘱严格配比，避免过稀或过浓。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"her2-material-mark\">储存要求：\u003C/span>未开封的粉剂须冷藏（2-8°C），避光保存。开瓶后应尽快使用，最长不超过24小时。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"her2-material-notice\">溶解、稀释过程只能由医务人员完成，患者勿自行操作！\u003C/span>\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        开封或稀释后的剩余药液不可再次保存或使用，以防失效或感染。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 04 药物相互作用及同时用药警示 -->\n  \u003Csection class=\"her2-material-section\">\n    \u003Cdiv class=\"her2-material-subtitle-bg\">\n      \u003Ch2 class=\"her2-material-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 药物相互作用与同时用药警示 ⚠️\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"her2-material-content\">\n      \u003Cp>\n        帕妥珠单抗和曲妥珠单抗可与多西他赛、卡铂等化疗药物联合使用，但存在药物间相互作用风险，尤其关注以下方面：\n      \u003C/p>\n      \u003Cul class=\"her2-material-ul\">\n        \u003Cli>\n          \u003Cspan class=\"her2-material-mark\">避免合用抗HER2以外的靶向药物，除非有明确方案和医生指导。\u003C/span>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"her2-material-mark\">联合药物需逐一稀释和分路静滴，不可混合同袋。\u003C/span>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"her2-material-mark\">部分降压药、心脏保护药可能影响药效和安全性，用药前需报备全部用药清单。\u003C/span>\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"her2-material-notice\">服用其他药物（如降压药、抗心律失常药）时，务必提前向医生报告！\u003C/span>\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        说明书与最新指南均未发现与食物的显著相互作用，但输注当天应清淡饮食，避免酒精。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 05 特殊人群用药调整须知 -->\n  \u003Csection class=\"her2-material-section\">\n    \u003Cdiv class=\"her2-material-subtitle-bg\">\n      \u003Ch2 class=\"her2-material-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 特殊人群用药调整须知 👩‍⚕️\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"her2-material-content\">\n      \u003Cp>\n        对于不同年龄及生理状况的患者，这类靶向药物的用法需特殊关注：\n      \u003C/p>\n      \u003Cul class=\"her2-material-ul\">\n        \u003Cli>\n          \u003Cspan class=\"her2-material-mark\">老年患者：\u003C/span>由于心功能下降及代谢减慢，偶需减量或延长观察，首次输注建议在监护下进行。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"her2-material-mark\">肝肾功能不全者：\u003C/span>轻中度者通常可使用，但具体剂量需遵医嘱调整，严重功能障碍者需谨慎。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"her2-material-mark\">孕妇、哺乳期禁用：\u003C/span>有致畸胎或婴儿风险，整个妊娠期和哺乳期必须严格禁止。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"her2-material-notice\">如有特殊人群服药需个体化，告知医生全部健康状况。\u003C/span>\n        \u003C/li>\n      \u003C/ul>\n      \u003C!-- 案例2 -->\n      \u003Cdiv class=\"her2-material-case\">\n        \u003Cstrong>案例：\u003C/strong>一位高龄患者在使用帕妥珠单抗联合曲妥珠单抗时监测心功能并按医嘱调整剂量，顺利完成疗程。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 06 常见不良反应及处理办法 -->\n  \u003Csection class=\"her2-material-section\">\n    \u003Cdiv class=\"her2-material-subtitle-bg\">\n      \u003Ch2 class=\"her2-material-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 常见不良反应及处理办法 😷\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"her2-material-content\">\n      \u003Cp>\n        两药虽然效果显著，但也存在一定不良反应。\u003Cbr>\n        \u003Cstrong>曲妥珠单抗：\u003C/strong>常见有发热、寒战、头痛、皮疹和注射相关反应。\u003Cbr>\n        \u003Cstrong>帕妥珠单抗：\u003C/strong>可见腹泻和皮疹。两药最受关注的不良反应是心脏毒性。\u003Cbr>\n        \u003Cspan class=\"her2-material-mark\">数据表明：\u003C/span>联合方案中注射反应率高达30%，心功能下降发生率约5-10%（参考Swain, S. M. et al., New England Journal of Medicine, 2015）。\n      \u003C/p>\n      \u003Cul class=\"her2-material-ul\">\n        \u003Cli>\n          \u003Cspan class=\"her2-material-mark\">常见处理做法：\u003C/span>注射中如出现发热、寒战、皮疹等，可短暂停药，症状缓解后再续用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"her2-material-mark\">严重反应：\u003C/span>如胸闷、呼吸困难、心跳失常等，立即停止输注，及时寻求医疗救治。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"her2-material-mark\">定期检测心功能：\u003C/span>每3-6个月随访一次心脏超声或血清心脏标志物。\n        \u003C/li>\n      \u003C/ul>\n      \u003C!-- 案例3 -->\n      \u003Cdiv class=\"her2-material-case\">\n        \u003Cstrong>案例：\u003C/strong>临床有患者在治疗第4次曲妥珠单抗时出现轻度发热与皮疹，经暂停输注和对症处理后恢复正常，未影响后续疗程。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 07 药品储存与过期处理准则 -->\n  \u003Csection class=\"her2-material-section\">\n    \u003Cdiv class=\"her2-material-subtitle-bg\">\n      \u003Ch2 class=\"her2-material-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 药品储存与过期处理准则 🗃️\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"her2-material-content\">\n      \u003Cp>\n        药效与安全离不开合理储存和及时更换：\n      \u003C/p>\n      \u003Cul class=\"her2-material-ul\">\n        \u003Cli>\n          \u003Cspan class=\"her2-material-mark\">未开瓶粉剂：\u003C/span>2-8°C冷藏，避免冷冻和光照，密封储存。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"her2-material-mark\">开瓶配制液：\u003C/span>必须在24小时内用完，多余药液废弃，切勿二次保存。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"her2-material-mark\">过期药如何处理：\u003C/span>勿自行丢弃或回收，建议交由医疗机构或专业药品回收单位处理。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        \u003Cspan class=\"her2-material-mark\">正确做法：\u003C/span>家庭无需储存此类药品，全部由医疗机构统一冷链管理。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 结尾总结与合理用药倡导 -->\n  \u003Csection class=\"her2-material-section\">\n    \u003Cdiv class=\"her2-material-summary\" style=\"background-color:#f5fafc;border-radius:12px;padding:26px 18px 20px 18px;margin-top:22px;\">\n      \u003Ch3 class=\"her2-material-h3\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">结语：安全第一，细节决定疗效\u003C/h3>\n      \u003Cp>\n        帕妥珠单抗和曲妥珠单抗的正确联合使用，极大改善了HER2靶向治疗效果。但安全细节绝不能忽视——用量依医嘱、严格注射方法、专人配制、定期复查、心脏监测、特殊人群个体化调整，这些都是确保安全与疗效的关键。遇到不良反应或疑问，一定联络医生或药师，切不可随意更改方案。\u003Cbr>\n        \u003Cspan class=\"her2-material-mark\" style=\"font-size:1.1em;\">无论药品科技多先进，安全用药始终是第一原则。让每一次用药更有效、更安心，是每一位患者和家属应共同关注的目标。\u003C/span>\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 参考文献区 -->\n  \u003Csection class=\"her2-material-section\">\n    \u003Cdiv class=\"her2-material-ref-bg\">\n      \u003Ch3 class=\"her2-material-h3\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">主要参考文献\u003C/h3>\n    \u003C/div>\n    \u003Cul class=\"her2-material-ref-ul\">\n      \u003Cli>\n        Swain, S. M., Baselga, J., Kim, S. B., et al. Per- turzumab, Trastuzumab, and Docetaxel in HER2-Positive Meta- static Breast Cancer. \u003Cem>New England Journal of Medicine\u003C/em>, 372(8):724-734, 2015.\n      \u003C/li>\n      \u003Cli>\n        Gianni, L., Pienkowski, T., Im, Y. H., et al. 5-year Analysis of Neoadjuvant Pertuzumab and Trastuzumab in Patients with HER2-positive Early Breast Cancer: A Randomized Phase II Study (NeoSphere). \u003Cem>Lancet Oncology\u003C/em>, 17(6):791-800, 2016.\n      \u003C/li>\n      \u003Cli>\n        Cardoso, F., Kyriakides, S., Ohno, S., et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. \u003Cem>Annals of Oncology\u003C/em>, 30(8):1194-1220, 2019.\n      \u003C/li>\n      \u003Cli>\n        National Comprehensive Cancer Network (NCCN) Guidelines. Breast Cancer. Version 1.2023.\n      \u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\n\u003C/div>\n\n\u003Cstyle>\n.her2-material-main {\n  font-family: 'Segoe UI', 'Helvetica Neue', Arial, 'PingFang SC', 'Microsoft YaHei', sans-serif;\n  color: #253343;\n  background: #fafbfc;\n  max-width: 780px;\n  margin: 24px auto 48px auto;\n  box-shadow: 0 6px 18px rgba(38, 91, 168, 0.07);\n  border-radius: 18px;\n  padding: 0 0 36px 0;\n}\n\n.her2-material-h1 {\n  font-size: 2.4em;\n  font-weight: bold;\n  letter-spacing: 1px;\n  text-align: center;\n  padding: 36px 18px 18px 18px;\n  margin: 0;\n  background: linear-gradient(90deg, #e5edf6 0%, #eaf3fb 100%);\n  border-top-left-radius: 18px;\n  border-top-right-radius: 18px;\n}\n\n.her2-material-lead {\n  font-size: 1.14em;\n  color: #326ba2;\n  background: #e8f2fa;\n  border-left: 4px solid #50a8e1;\n  margin: 22px 26px 18px 26px;\n  padding: 16px 20px;\n  border-radius: 9px;\n  line-height: 1.7;\n}\n\n.her2-material-section {\n  margin-top: 1.8em;\n  margin-bottom: 0.8em;\n  padding: 0 26px;\n}\n\n.her2-material-subtitle-bg {\n  background: linear-gradient(100deg, #f3f7fa 60%, #e0eef9 120%);\n  border-radius: 7px;\n  margin-bottom: 12px;\n  padding: 1.5em 1.3em 0.6em 1.2em;\n}\n\n.her2-material-h2 {\n  font-size: 1.35em;\n  color: #3162a2;\n  font-weight: 600;\n  margin: 0;\n  letter-spacing: 1px;\n}\n\n.her2-material-h3 {\n  font-size:1.16em;\n  color:#2777a5;\n  font-weight: 600;\n  margin-top:0;\n  margin-bottom:8px;\n  letter-spacing:.5px;\n}\n\n.her2-material-content {\n  font-size:1.07em;\n  letter-spacing:0.3px;\n  line-height:1.8;\n  padding-bottom: 8px;\n  color: #314154;\n}\n\n.her2-material-ul {\n  padding-left: 1.2em;\n  margin: 0.2em 0 1em 0.1em;\n}\n\n.her2-material-ul li {\n  margin-bottom: 0.5em;\n  padding-left:0.2em;\n}\n\n.her2-material-mark {\n  color:#155ca7;\n  font-weight:600;\n}\n\n.her2-material-notice {\n  color: #d44848;\n  font-weight: bold;\n  font-size:0.98em;\n  margin-left: 0.1em;\n}\n\n.her2-material-emoji {\n  display:inline-block;\n  margin-left:0.2em;\n  margin-right:0.08em;\n}\n\n.her2-material-case {\n  background: #edf6ff;\n  border-left: 4px solid #98c8f9;\n  color: #356290;\n  font-size: 1.02em;\n  padding: 0.7em 1.1em 0.54em 1.1em;\n  margin: 1em 0 1.4em 0;\n  border-radius: 7px;\n  font-style: italic;\n}\n\n.her2-material-ref-bg {\n  background: linear-gradient(93deg, #e8f4fc 55%, #e3effa 115%);\n  padding: 1.12em 1.2em 0.7em 1.18em;\n  border-radius: 7px;\n}\n\n.her2-material-ref-ul {\n  font-size:0.96em;\n  color:#25507b;\n  padding-left:1.4em;\n  margin:0.8em 0 0.45em 0;\n}\n\n.her2-material-summary {\n  font-size:1.15em;\n  letter-spacing:.6px;\n  line-height:1.8;\n}\n\n@media (max-width:900px) {\n  .her2-material-main {\n    max-width:98%;\n    margin:10px auto 32px auto;\n    padding: 0 0 24px 0;\n  }\n  .her2-material-section { padding: 0 8px; }\n  .her2-material-lead { margin-left: 8px; margin-right: 8px; }\n}\n\n@media (max-width:540px) {\n  .her2-material-h1 {\n    font-size: 1.32em;\n    padding: 18px 5px 13px 5px;\n  }\n  .her2-material-lead {\n    font-size: 1em;\n    padding: 10px 8px;\n  }\n}\n\n\u003C/style>\n","\u003C!-- 乳腺癌HER2阳性患者靶向药物科普专题：帕妥珠单抗与曲妥珠单抗安全用药全攻略 -->\n\n\u003Cdiv class=\"her2-material-main\">\n\n  \u003Ch1 id=\"materia",529,"2025-08-21 15:20:10","帕妥珠单抗, 曲妥珠单抗, HER2阳性乳腺癌, 靶向治疗, 不良反应","本文提供帕妥珠单抗与曲妥珠单抗的使用指南，涵盖作用机制、用药方法与注意事项，确保HER2阳性乳腺癌患者安全有效地进行靶向治疗。","2025-08-26 07:56:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]